GlassScriptPhysician profile
Ghada Kassab
NPI 1023278504
$3,175.03
in general payments reported to CMS, 2019-2025
24 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $599 · 2020: $506 · 2021: $763 · 2022: $381 · 2023: $414 · 2024: $370 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $926.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $405.50 | 2021-2024 | Otezla |
| Genzyme Corporation | $359.96 | 2019-2024 | |
| Dermira, INC. | $318.01 | 2019-2020 | |
| Leo Pharma INC. | $259.42 | 2019-2025 | Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $233.50 | 2019-2023 | Jublia, Arazlo |
| Biofrontera INC. | $232.05 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Pfizer INC. | $216.84 | 2019-2023 | |
| Arcutis Biotherapeutics, INC. | $214.22 | 2023-2025 | Zoryve |
| Abbvie INC. | $142.46 | 2021-2025 | |
| Incyte Corporation | $123.52 | 2022-2024 | Opzelura |
| Sanofi-Aventis U.S. LLC | $101.36 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $94.47 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $93.41 | 2020-2022 | |
| Vyne Pharmaceuticals INC. | $70.55 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $50.60 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dusa Pharmaceuticals, INC. | $45.24 | 2019 | |
| Dermavant Sciences, INC. | $32.09 | 2023-2024 | Vtama |
| Organon LLC | $31.52 | 2025 | Vtama |
| Allergan, INC. | $30.47 | 2021 | |
| Verrica Pharmaceuticals INC. | $25.73 | 2023 | Ycanth |
| Lilly USA, LLC | $24.53 | 2023 | Taltz |
| Galderma Laboratories, L.P. | $24.47 | 2021-2022 | |
| Merz North America, INC. | $22.93 | 2025 | |
| Strata Skin Sciences, INC. | $22.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghada Kassab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.